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ABSTRACT 
Background: A key manifestation of Parkinson’s disease (PD) is visual impairment. Cognitive impairment has been found to overlap 
with convergence insufficiency (CI) in patients with PD and is associated with significantly greater near point convergence (NPC) 
distance. Difficulty in reading and diplopia were the most common symptoms of CI in PD. The prevalence of CI is greater among 
patients with PD. Therefore, this study aimed to assess the relationship between PD and CI.  
Methods: Studies that had included data on CI, NPC, or both were selected by searching PubMed/MEDLINE and clinicaltrails.gov, 
without any timeline or language limitation. The following terms were used in PubMed/MEDLINE search: ‘Clinical Trials’, ‘Parkinson’s 
Disease’, and ‘Convergence Insufficiency’. For clinical trials.gov database, the terms ‘Parkinson’s Disease’, ‘Convergence Insufficiency’, 
and ‘Completed Studies’ were used. Only those studies with control subjects were included. PubMed/MEDLINE search yielded 1,563 
articles, but no article was found in the clinical trails.gov search.  
Results: Overall, there were 1,563 articles; among them, 12 articles met the inclusion criteria. Nine articles were selected based on 
their data concerning CI or NPC distance (cm) and PD. Relative to the control group, the PD group had high CI. In addition, PD group 
showed increase in NPC distance than the control group. 
Conclusions: These data suggest that the patients with PD had an increased likelihood of developing CI visual symptoms, and increased 
NPC distance than healthy controls. These findings indicate that regular eye examination is very important for patients with PD.  
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INTRODUCTION 
Parkinson’s disease (PD) is the second most common 
neurodegenerative disorder. Visual impairment is a 
primary manifestation of PD. The prevalence of 
convergence insufficiency (CI) is greater in patients with 
PD. Cognitive impairment (CIM) has been found to 
commonly overlap with CI in PD patients and is associated 
with a significantly greater distance of near point 
convergence (NPC). Eye clinicians should consider the 
possibility of a higher incidence of CIM in patients with PD 
and CI [1]. Since CI is common among PD cases and the 
most commonly cited symptoms associated with CI in PD 
were difficulty in reading and diplopia [2-4], this overview 
examined the relationship between PD and CI. 
METHODS 
Studies with data on CI, NPC, or both were selected from the 
PubMed/MEDLINE and clinicaltrails.gov databases. In the 
PubMed/MEDLINE search, the following terms were used: 
‘Clinical Trials’, ‘Parkinson’s Disease’, and ‘Convergence 
Insufficiency’. For clinical trials.gov data base: ‘Parkinson’s 
Disease’, Convergence Insufficiency’, and ‘Completed 
Studies’ were used. The studies which included control 
subjects were recognized for further evaluation.  There were 
no limitations with respect to the timeline or language. 
RESULTS  
The PubMed/MEDLINE search yielded 1,563 articles, but 
no records were found in the clinical trails.gov search. Out 
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of 1563 records found in PubMed/MEDLINE, the full texts 
of 12 articles were screened as per the defined eligibility 
criteria. Following the exclusion of case reports, letters to 
editorials, and studies without a control group, nine 
articles were selected for the current study [3, 5, 6, 8, 11, 
12, 14-16]. 
We retrieved data from the CI screening survey and NPC. 
Altogether, these nine studies recruited 1547 patients 
with PD and 921 subjects as controls. Compared to the 
control group, a greater number of patients with PD had 
CI, decreased convergence amplitudes, or more common 
oculomotor symptoms [3, 5, 6, 11, 12, 14, 16]. In addition, 
the PD group showed increased NPC distances [3, 12, 14, 
16]. Likewise, more patients with PD had scores on the 
Convergence Insufficiency Symptom Survey (CISS)-15 of 
≥21 compared with controls [8, 12, 15, 16]. Table 1 
summarizes the characteristics and the main findings from 
the nine primary included studies [3, 5, 6, 8, 11, 12, 14-16].  
DISCUSSION 
Relative to the control group, the PD group had a higher 
number of CI. These data suggest that the patients with 
PD had an increased likelihood of developing CI visual 
symptoms, and increased NPC distance than healthy 
controls. The eye examination, especially the binocular 
vision test, for patients with PD cannot be 
overemphasized.  
PD has been associated with diplopia, reduced visual 
acuity, pupil abnormalities, saccade abnormalities, 
smooth pursuit eye movement disorders, CI, vergence 
abnormalities, strabismus, slower reading time, and 
vertical gaze abnormalities [2, 17, 18]. Since diplopia has 
been reported in PD, and diplopia is one of the 
manifestations of CI, there is a clear correlation between 
diplopia and CI in PD [3, 14]. Therefore, we used CI as a 
keyword in our literature search. Other manifestations 
should be reviewed in future studies such as visual 
hallucinations and diplopia [3-5, 11].  
Binocular vision tests such as positive fusional vergence 
(PFV) and NPC are required for the diagnosis of CI. It has 
been emphasized that simple reading tasks using 120 
single-digit numbers can be used as a screening tool in 
clinical settings to assess functional ocular motor 
difficulties in PD, which can have a significant impact on 
the quality of life [19]. Other tests that may be used as 
screening tools are electrophysiological recordings, such 
as flash pattern electrooculography, multifocal 
electroretinography, and visual evoked potential [12, 20].  
The data presented in this paper suggest that in patients 
with PD, the likelihood of CI visual symptoms and 
increased NPC distance is greater than that in the control 
group. Therefore, regular eye examinations are important 
for patients with PD. In addition, patients with objective 
findings of CI, irrespective of being symptomatic or not, 
might be at a higher risk of CIM. Although non of included 
studies evaluated the association between CIM and CI (see 
Table 1), still eye clinicians should be highly aware of CIM 
in patients with CI [11, 21], while waiting for future studies 
to shed light on the subject. 
Some limitations on the interpretation of our findings 
need to be noted. The selected studies for the CI in PD 
used various tools [3, 5, 6, 8, 11, 12, 14-16] to assess the 
subjects, and not all of the included studies had details of 
NPC (see Table 1). However, by summarizing these 
findings, we aimed to highlight the urgency of binocular 
vision examination in patients with PD. Also, the 
availability of only nine reports on the topic highlights the 
urgent need for more such clinical research on this 
subject. The strength of this report would be drawing 
attention to a novel association between CI and PD. 
 
CONCLUSIONS 
The prevalence of CI-type visual symptoms is higher in 
individuals with PD. We emphasize the importance of regular 
eye examinations for individuals with PD, especially binocular 
vision tests. Our results highlight the need for more clinical 
trials to further evaluate CI in patients with PD.  
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Table 1. Characteristics of the included studies in this report. 
First author Study type  Diagnostic tool Age (Years) Subjects Main findings 







Mean ± SD  
PD with diplopia, 
72±9 
PD without diplopia, 
73±8 
CS, 70±8 







NPC (cm): median (IQR) 
PD with diplopia, 13 (11); PD without diplopia, 7 (10); CS, 6 (11) 
CI, n: PD with diplopia, 15; PD without diplopia, 2; CS, 5. 
Note: Only, 44% percent of patients with PD and diplopia had visual 
hallucinations. Median cognitive function using MoCA was 23 and 28 in 
PD and CS, respectively. 
Biousse et al. [5] Case-control  UPDRS motor 
score  
Mean age, range:  
PD: 61 (34-79) 
CS: 58 (37-74) 
30 PD 
31 CS 
CI: PD, n = 7; CS, n= 6 (P = 0.704). 
Decreased NPC: PD, n= 9; CS, n= 7 (P = 0.944). 
Decreased CAs: PD, n = 24; CS, n = 8 (P < 0.001). 
Note: Most cases with PD had normal NPC with decreased CAs. Patients 
with PD were in an early stage of disease, and details of CIM status in 
recruited cases was not mentioned in this paper. Twenty-five percent 
of patients had formed visual hallucinations, but no one developed 
dementia after two years of follow-up. 




VIPD-Q Median (IQR) [Range]  
PD: 70 (12.5] [33-93]     
CS: 70 (13.8) [31-94] 
848 PD  
250 CS  
Oculomotor symptoms were significantly (P < 0.001) more common in 
patients with PD patients than in CS. 
Note: Visual hallucinations were found in 22% of patients with PD 
versus 2% of CS (P < 0.001). This paper does not give details of CIM 
status in recruited cases. 
Law et al. [8] Observational 
multicenter 
cross-
sectional       
CISS-15  Mean ± SD 
PD: 67.3 ± 8.9  
CS: 67.2 ± 8.7 
300 PD 
300 CS 
Significantly (P = 0.001) more Patients with PD had a score of ≥21 on the 
CISS-15 compared with CS. 
Note: Cases with MMSE scores < 14 have been excluded. 
Nowacka et al. 
[11] 




Mean ± SD:  
PD: 68.5±10.2 
CS: 68.6±9.8 
100 PD  
100 CS  
CI: PD, 24.5%; CS, 9.7% (P < 0.001). 
Note: Four percent of patients with PD had visual hallucinations. This 
paper does not give details of CIM status in recruited cases, and stage 
of PD was quite low. 
Irving et al. [12] Case-control CISS-15 Mean ± SD:  
PD: 67.4 ± 8.5 




Subjective NPC (cm): Mean ± SD  
PD, 11.2 ± 6.2; CS, 4.4 ± 3.7 (P ≤ 0.001).  
Objective NPC (cm): Mean ± SD 
PD, 14.5 ± 4.4; CS, 8.2 ± 1.0 (P ≤ 0.001).  
Significantly (P ≤ 0.001) more patients with PD (43.8%) had CI compared 
with CS (16.3%). Significantly (P ≤ 0.001) more patients with PD (53.8%) 
had scores on the CISS-15 of ≥21 compared with CS (18.8%). 
Note: Cases with MMSE scores < 24 have been excluded. 
Repka et al. [14] Case-control   PD staging was 
assessed with 
the modified 




PD: 68 (45-80, 70)  
CS: 65 (47-77, 65)  
39 PD  
39 CS 
NPC in cm, mean (range): PD, 15 (4-22); CS, 9 (4-33) (P = 0.002). 
CI was significantly (P < 0.001) more common in the patients with PD 
(n= 12) than in CS (n= 0). 
Note: Increasing severity of PD correlated with the presence of CI and 
deterioration of visual acuity. This paper does not give details of CIM 
status in recruited cases. 
Kergoat et al. [15] Case-control CISS-15 Mean ± SD:  
PD: 1.2 ± 10.4  
CS: 70.5 ± 9.2  
82 PD 
82 CS  
 
Significantly (P ≤ 0.05) more patients with PD (45.1%) had scores on the 
CISS-15 of ≥ 21 against CS with co-existing oculovisual condition (17.1%) 
Note: This paper does not give details of CIM status in recruited cases. 
Almer et al. [16] Prospective 
comparative 
case series 
PD staging was 
assessed with 
the Hoehn and 
Yahr (H-Y) scale 
and UPDRS 
motor score 
Mean ± SD:  




NPC (cm): Mean ± SD 
PD “on” dopaminergic medication, 13.1±9.1 (PD versus CS, P = 0.079) 
PD “off” dopaminergic medication, 18.1±12.2 (PD versus CS, P= 0.002) 
CS, 8.7±4.5 
CA (prism diopters): Mean ± SD 
PD “on” dopaminergic medication, 14.8±10.3 (PD versus CS, P = 0.003) 
PD “off” dopaminergic medication, 10.7±9.0 (PD versus CS, P = 0.0007) 
CS, 24.1±8 
Note: No correlation found between duration or severity of PD and the 
size of the exodeviation or CI. This paper does not give details of CIM 
status in recruited cases 
Abbreviations: CA, convergence amplitudes; CI, convergence insufficiency; CIM, Cognitive impairment; CISS-15, Convergence Insufficiency Symptom Survey; cm: 
centimeter; CS, Control Subjects; IQR, the interquartile range; MMSE, mini mental state examination;  MoCA, Montreal Cognitive Assessment; n, number; NPC, 
near point of convergence; PD, Parkinson’s Disease; SD, standard deviation; UPDRS, the Unified Parkinson’s Disease Rating Scale; VIPD-Q, The Visual Impairment 
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